Compare BridgeBio Pharma Inc (BBIO) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Starbucks Corp — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while Starbucks Corp trades at $106.73 (market cap $121.59B). The key difference: Starbucks Corp is far larger — about 7.4× BridgeBio Pharma Inc's market cap, and Starbucks Corp pays a 2.33% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | SBUX | |
|---|---|---|
Market Cap | $16.36B | $121.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $108.37 |
52-Week Low | $47.29 | $78.46 |
Enterprise Value | $18.14B | $140.42B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.33% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
